{"entity":{"id":"limited-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (small-cell lung cancer)","aka":["limited-stage","limited stage","LS-SCLC","extensive-stage","extensive stage","ES-SCLC","very limited stage","thoracic radiotherapy","consolidative thoracic radiotherapy","limited-vs-extensive-stage"],"tldr":"Small-cell lung cancer uses a two-way split instead of the usual four stages: limited (confined to one side of the chest and treatable within one radiation field, about a third of patients) or extensive (everything else).","summary":"Limited-stage disease receives concurrent platinum-etoposide and thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily) with curative intent, now followed by durvalumab consolidation (ADRIATIC), and cures 25-35%; extensive-stage disease receives platinum-etoposide with atezolizumab or durvalumab (IMpower133, CASPIAN), responds in most patients and relapses in most within a year, with tarlatamab now the preferred second-line drug. Prophylactic cranial irradiation or MRI surveillance follows response in both. TNM staging is applied in parallel but the two-stage system still drives treatment.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Small-cell_carcinoma","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Small-cell_carcinoma"}],"tags":[],"related":["chemoradiation","prophylactic-cranial-irradiation","consolidation-therapy"],"cancers":["sclc"],"sections":["radiation","chemotherapy"],"technologies":[],"targets":[],"drugs":["durvalumab","atezolizumab","tarlatamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["adriatic","convert"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Treatment jargon"},"route":"/terms/limited-extensive-stage/","neighbours":{"term":[{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"},{"id":"consolidation-therapy","kind":"term","name":"Consolidation therapy","route":"/terms/consolidation-therapy/"}],"technology":[{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/"}],"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/"},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"trial":[{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/"},{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/"}]}}